AU2021312238A1 - Methods and compositions for treatment and prevention of coronavirus infection - Google Patents

Methods and compositions for treatment and prevention of coronavirus infection Download PDF

Info

Publication number
AU2021312238A1
AU2021312238A1 AU2021312238A AU2021312238A AU2021312238A1 AU 2021312238 A1 AU2021312238 A1 AU 2021312238A1 AU 2021312238 A AU2021312238 A AU 2021312238A AU 2021312238 A AU2021312238 A AU 2021312238A AU 2021312238 A1 AU2021312238 A1 AU 2021312238A1
Authority
AU
Australia
Prior art keywords
ace2
coronavirus
cov
protein
fusion polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021312238A
Other languages
English (en)
Inventor
Gordon J. Freeman
James Torchia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2021312238A1 publication Critical patent/AU2021312238A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021312238A 2020-07-20 2021-07-20 Methods and compositions for treatment and prevention of coronavirus infection Pending AU2021312238A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053817P 2020-07-20 2020-07-20
US63/053,817 2020-07-20
US202163150686P 2021-02-18 2021-02-18
US63/150,686 2021-02-18
PCT/US2021/042372 WO2022020353A2 (en) 2020-07-20 2021-07-20 Methods and compositions for treatment and prevention of coronavirus infection

Publications (1)

Publication Number Publication Date
AU2021312238A1 true AU2021312238A1 (en) 2023-02-23

Family

ID=77301019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021312238A Pending AU2021312238A1 (en) 2020-07-20 2021-07-20 Methods and compositions for treatment and prevention of coronavirus infection

Country Status (8)

Country Link
US (1) US20230272359A1 (https=)
EP (1) EP4182458A2 (https=)
JP (1) JP2023535695A (https=)
KR (1) KR20230058045A (https=)
CN (1) CN116171324A (https=)
AU (1) AU2021312238A1 (https=)
CA (1) CA3189732A1 (https=)
WO (1) WO2022020353A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
CA3185230A1 (en) * 2020-07-06 2022-01-13 Shengjiang Liu Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
EP4507787A1 (en) * 2022-04-13 2025-02-19 Paradigm Immunotherapeutics, Inc. Methods of preventing or treating infection by respiratory viruses including sars-cov-2
CN119265271B (zh) * 2024-12-09 2025-04-22 上海益诺思生物技术股份有限公司 一种评价ade效应的系统及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
AU4691900A (en) * 1999-05-13 2000-12-05 Zymogenetics Inc. Zace2: a human metalloenzyme
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US20070185044A1 (en) * 2005-03-08 2007-08-09 Dobie Kenneth W Modulation of ace2 expression
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
HK1209034A1 (en) * 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
EP2972375A2 (en) * 2013-03-13 2016-01-20 Creatics LLC Methods and compositions for detecting pancreatic cancer
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
WO2021183404A1 (en) * 2020-03-07 2021-09-16 Planet Biotechnology, Inc. Ace2-fc fusion proteins for sars-cov-2 mitigation
CN113444710A (zh) * 2020-03-25 2021-09-28 上海英脉德医疗科技有限公司 ACE2-Fc融合蛋白及其用途
WO2021202427A2 (en) * 2020-03-29 2021-10-07 R-Pharm Overseas, Inc. Ace2-derived composition and use thereof
KR20230015365A (ko) * 2020-05-22 2023-01-31 포르미콘 아게 Ace2 융합 단백질 및 이의 용도

Also Published As

Publication number Publication date
WO2022020353A3 (en) 2022-03-10
US20230272359A1 (en) 2023-08-31
CA3189732A1 (en) 2022-01-27
CN116171324A (zh) 2023-05-26
WO2022020353A2 (en) 2022-01-27
JP2023535695A (ja) 2023-08-21
EP4182458A2 (en) 2023-05-24
KR20230058045A (ko) 2023-05-02

Similar Documents

Publication Publication Date Title
US20230272359A1 (en) Methods and compositions for treatment and prevention of coronavirus infection
US20230218743A1 (en) Peptide Therapeutics Against SARS-COV-2 Spike Protein
JP6621741B2 (ja) Ｃｔｌａ−４に対する親和性が改善したｃｄ８６バリアント
KR20250160211A (ko) 다중-사슬 키메라 폴리펩타이드 및 이의 용도
CN111647082A (zh) 抗人il-4ra的抗体及其用途
CA3147291A1 (en) Immunostimulatory multimeric binding molecules
CN106456734A (zh) Ox40l融合蛋白及其用途
WO2021205184A1 (en) Polypeptide
WO2022177870A1 (en) Multimeric sars-cov-2 binding molecules and uses thereof
AU2012322445B2 (en) Canine/feline CD20 binding epitope and compositions for binding thereto
TW201827461A (zh) 抗chikv抗體及其用途
CN118994380A (zh) 抗新型冠状病毒抗体及其应用
CN118510893A (zh) 包括细胞进入受体和Fc区组分的抗病毒剂
WO2023039667A1 (en) Multivalent polypeptide constructs capable of binding viral spike proteins and methods of using the same
CN101883787B (zh) 一种可溶性tnf受体突变体
CN110938146B (zh) Tim-3单域抗体及其应用
US20240109954A1 (en) Fc-enhanced antibodies for prevention and treatment of ebola virus infection
TW202228765A (zh) 重組ACE2-Fc融合分子以及製造與使用其的方法
CN107207583A (zh) 对呼吸道合胞体病毒(rsv)的f蛋白具有特异性的人单克隆抗体
CN115304672A (zh) 冠状病毒抗体及其应用
WO2022022526A1 (zh) 抗her2抗体及其应用
EP4335870A1 (en) Peptide therapeutics against sars-cov-2 spike protein
US20240209065A1 (en) Secretory iga antibodies against covid infection
WO2026046399A1 (en) Anti-dll3 antibodies and use thereof
CN102844330B (zh) 针对hiv p17蛋白、能够中和p17与p17受体（p17r）结合的单克隆抗体